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Genovefa Anna Papanicolaou1The Toll-like receptor 4 (TLR4) gene is a major recognition receptor for lipopolysaccharide (LPS). In a pilot
prospective study, we examined the association of 2 TLR4 polymorphisms (Asp299Gly and Thr399Ile) in the
donor or the recipient with Gram-negative bloodstream infection (BSI) in 77 allogeneic hematopoietic stem
cell transplant (HSCT) patients. Heterozygosity at both loci was defined as ‘‘risk genotype.’’ The cumulative
incidence of infection was estimated by treating death prior to infection as a competing risk event and
compared between relevant groups using a modified chi-square test. Nine patients had the risk genotype
based on donor and 5 based on recipient genotype data. Donor risk genotype showed marginal statistical
significance (0.06) in univariate analysis, but not in multivariate analysis. A larger study is required to validate
our findings and define genetic susceptibility to this serious infection in HSTC patients.
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marrow transplantationINTRODUCTION
Bloodstream infection (BSI) by Gram-negative
organisms occurs in approximately 20% of allogenic he-
mopoietic stem cell transplant (HSCT) recipients [1] .
Toll-like receptor 4 (TLR4) has been shown to be
a major recognition receptor for lipopolysaccharide
(LPS), a highly conserved component of the cell wall
of Gram-negative pathogens. The mouse strains
C3H/HeJ (TLR4 Pro712His) and C57BL/10ScCR(de-
letion ofTLR4 locus) are hyporesponsive to LPS [2]. In-
terestingly, these strains are very susceptible to fatal
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6/j.bbmt.2009.04.012Two polymorphic point mutations at nucleotides
A896G and C1196T in the cDNA of human TLR4
encode for amino-acid substitutions Asp299Gly and
Thr399Ile, respectively, within the extra-cellular do-
main of TLR4. Both mutations are predicted to affect
a ligand binding region and a co-receptor biding region,
respectively [3]. Primary human epithelial cells and alve-
olar macrophages with these mutations have blunted re-
sponses to LPS. Individuals with these mutations have
hyporesponsiveness to inhaled LPS [4].
TLR4Asp299Gly and the co-segregating mutation
TLR4Thr399Ile are found in approximately 6% to
10% of Caucasians [5,6]. These polymorphic forms of
TLR4 have been associated with an increased incidence
of Gram-negative infections and sepsis, and more
recently with an increased susceptibility to Crohn’s dis-
ease [5,7]. Conversely, individuals with these mutations
appear to be at decreased risk for certain inflammatory
diseases including atherosclerosis and rheumatoid
arthritis [8,9]. Thus TLR4 signaling appears to play
an important role in the balance between the ability to
control infections and the pathogenesis of inflamma-
tory diseases. Functional polymorphisms with no
apparent effect on immunocompetent individuals may
become clinically relevant in immunocompromised
patients, such as allogeneic HSCT recipients.
We studied prospectively a cohort of 105 alloge-
neic HSCT to determine any association between
the TLR4Asp299Gly and Thr399Ile mutations in
Biol Blood Marrow Transplant 15:1130-1133, 2009 1131TLR4 Mutations and Bacteremia in BMTthe donor or the recipient with development of Gram-
negative bloodstream infection post HSCT.MATERIALS AND METHODS
Study Patients
The study was approved by the Memorial Sloan-
Kettering Cancer Center (MSKCC) Institutional Re-
view Board. One hundred and five non-consecutive,
non-selected patients who received allogenic HSCT
at MSKCC from October 2003 through December
2004 were enrolled in a prospective study. The objec-
tive of the study was to assess the role of genetic poly-
morphisms in innate immune genes in susceptibility
to specific infections post HSCT.
Case Definition
Gram-negative BSI was defined as any positive
blood culture for a Gram-negative organism treated
with antibiotics. Follow-up of the patients ranged
from 60 days to 2 years post HSCT.
Genotyping
DNA source
After signing informed consent, 5-10 mL of pe-
ripheral blood was obtained from the patients once
prior to stem cell infusion (for mutational analysis of
the recipient) and once after full chimerism was docu-
mented (for mutational analysis of the donor). Geno-
mic DNA was extracted from the peripheral blood
using the PureGene (Gentra Systems, Minneapolis,
MN) and stored at 220C.
Genotyping
A 1420-bp fragment of TLR4 containing TLR4
896A.G (Asp299Gly) and 1196C.T (Thr399Ile)
was amplified from genomic DNA by the polymerase
chain reaction (PCR) using the primers forward: 50-
TTTCTAATCTGACCAATCTAG-30 and reverse:
50-ACTACAAGCACACTGAGGA-30.
The PCR reaction was performed in a final volume
of 50 mL containing 100 ng of DNA, dNTPs at a final
concentration of 3 mM, 15 picomoles of each primer,
and 1.5 units of Taq DNA polymerase (Mercury Prod-
ucts, Continental Lab Products, San Diego, CA).
Polymerase chain reaction (PCR) conditions were:
denaturation at 94C for 20 seconds, annealing at
60C for 20 seconds, and extension at 72C for
1 minute for 35 cycles. Final extension was conducted
at 72C for 5 minutes. The PCR product was purified
for sequencing reaction using the Montage PCR96
plates (Millipore, Bedford, MA). Both strands of
the PCR product were sequenced using primers for-
ward: 50-TTGGTTCTGGGAGAATTTAG-30 andreverse: 50-TGAAAACTCACTCATTTGTTT-30.
Sequencing was performed on an ABI 377 sequencer
using Big Dye terminator chemistry (Applied Biosys-
tems, Bedford, MA) according to the manufacturer’s
recommendations. Electropherograms were analyzed
using the Phred and Phrap softwares (www.phrap.org).
The reference sequence NM_138554 was used for
TLR4 (http://www.ncbi.nlm.nih.gov/). Screening
was performed blinded to the identity of the samples.Statistical Analysis
Genotypes of the donor and the recipient were re-
corded.
For the analysis the data from the 2 single nucleo-
tide polymorphisms (SNPs) were summarized into 1
SNP score as follows: Genotypes heterozygous for
the minor allele at both SNP were defined as ‘‘risk ge-
notype. All other genotypes were defined as ‘‘no risk
genotype.’’
The association between Gram-negative BSI and
risk genotype was investigated separately for the geno-
types of donors and recipients. The outcome of inter-
est was Gram-negative BSI, measured as the time
elapsed (in days) between the date of stem cell infusion
and date of Gram-negative BSI or date of death (if the
patient died prior to the onset of infection) or the last
follow-up date (if the patient was alive and infection
free). The cumulative incidence of infection was esti-
mated by treating death prior to the onset of
infection as a competing risk event, and compared
between relevant groups using a modified chi-squared
test. P-value\.05 was considered statistically signifi-
cant [10]. Univariate and multivariate analysis were
used to examine the relationship between BSI and
putative risk factors.RESULTS
Study Patients
Genotypes were available for 77 donor-recipient
pairs. Thus the sample size is 77 patients. The character-
istics of the patients are shown on Table 1. The risk ge-
notype was present in 9 (11.6%) patients based on donor
genotype data and 5 (6.4%) patients based on recipient
genotype data. Fifteen patients developed BSI during
the study period. Five BSI occurred before neutrophil
engraftment and 10 after neutrophil engraftment a me-
dian 79 days (range: 37-381 days) after HSCT. The
causative organisms were enteric Gram-negatives (11)
and non-fermenting Gram-negative rods (4).
Four groups of patients were defined based on the
presence of risk genotype in donor and recipient
(Table 2). Fifteen patients had BSI, 14 died prior to
infection, and 48 patients were alive at the end of the
follow-up period. Among the 15 patients with BSI, 4
Table 1. Characteristics of the Patients (n 5 77)
Variable
Total Number
of Patients
Race White non-Hispanic 57
Other 20
Conditioning type Myelo ablative 64
Reduced intensity 13
Donor type Matched related 33
Matched unrelated 27
Mismatched 17
Acute GVHD grade II,III,IV 13
0,1 64
missing 2
T cell depletion Yes 46
No 31
‘‘Risk genotype’’* donor Yes 9
No 68
‘‘Risk genotype’’ recipient Yes 5
No 72
Bloodstream infection Yes 15
No and alive 48
Dead without infection 14
GVHD indicates graft-versus-host disease.
*Risk genotype: Yes: TLR4 Asp299Gly and Thr399Ile.
No: all others.
Table 3. Univariate Analysis of Risk Factors for Bloodstream
Infection.
Variable
P-Value
from Modified
Chi-Squared Test
Race Other
White non-Hispanic .89
T cell depletion No
Yes .51
Stem cell source Nonblative
Ablative .69
Donor type Other
Matched relative .28
Matched nonrelated .86
Acute GVHD 2,3,4
(2 missing subjects
excluded)
0,1 .71
Donor risk genotype No
Yes .06
Recipient risk genotype No
Yes .25
GVHD indicates graft-versus-host disease; SNP, single nucleotide
polymorphism.
Outcome is time-to-bloodstream infection. Death prior to infection is
treated as a competing risk factor.
Table 4. Multivariate Analysis of Risk Factors for Blood-
stream Infection
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none (0%) on the recipient. Among the 14 patients
who died, none had risk genotypes based on the donor,
and 1 based on the recipient. Among the 48
patients alive without infection, 5 (10.6%) had a risk
genotype based on the donor, and 4 (8.5%) based on
the recipient.
Univariate analysis results of each putative risk fac-
tor for BSI are given in Table 3. The only factor that
showed marginal statistical significance was presence
of risk genotype in the donor.
Since risk genotype in the donor (but not in the re-
cipient) showed marginal statistical significance in the
univariate analysis, we included donor risk genotype in
the multivariate model. All other risk factors were also
included in the multivariate model because they are
deemed putative risk factors, even though they did
not exhibit statistical significance in the univariate
analyses (Table 4). Donor risk genotype did not
show statistical significance in multivariate analysis.Variable Hazard Ratio 95% CI P-Value
Race Other 1.00
White non-Hispanic 0.57 0.13-2.71 .49
T cell depletion No 1.00
Yes 1.04 0.33-3.28 .95
Stem cell source Other 1.00
Myeloablative 0.85 0.18-3.92 .84DISCUSSION
Genetic variants in immune response genes can
influence the outcome of HSCT independent ofTable 2. Infection by Risk Genotype in Donor/Recipient
Donor/Recipient
Risk Genotype
Status No/No Yes/No No/Yes Yes/Yes
N5 66 N5 6 N5 2 N5 3
Alive/no BSI 42 2 1 3
BSI 11 4 0 0
Dead/no BSI 13 0 1 0
BSI indicates bloodstream infection.HLA match status [11]. BSIs by Gram-negative organ-
isms are associated with substantial morbidity and
mortality. The inflammatory response to Gram-
negative bacteria has been mainly attributed to lipo-
polysaccharide (LPS), a highly conserved glycolipid
component of the cell wall [12]. Key components of
the innate immune response to LPS are TLR4, the li-
popolysaccharide binding protein (LBP) the secreted
protein MD-2, and the TLR4 co-receptor CD14
[13]. It is likely that genetic variants in 1 or more genes
affecting the interaction of these molecules may
contribute to susceptibility or outcome of infections
by Gram-negative organisms.
A retrospective study in HSCT, reported a trend
towards reduced graft-versus-host disease (GVHD)Donor type Mismatched 1.00
Matched related 0.40 0.03-5.45 .49
Matched unrelated 1.07 0.56-2.03 .84
Acute GVHD 2,3,4 1.00
0,1 0.94 0.24-3.66 .93
Donor risk genotype No 1.00
Yes 3.38 0.84-13.63 .09
GVHD idicates graft-versus-host disease; CI confidence interval.
Outcome is time-to-bloodstream infection. Death before infection is
treated as a competing risk factor.
Two patients with missing acute GVHD are excluded from the analysis.
Hence, the effective sample size is 75 patients.
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Asp299Gly mutation. The same study showed a trend
for higher incidence of Gram-negative infections if the
donor or the recipient were heterozygous for the same
mutation [14].
In our prospective study study we analyzed 77
HSCT patients to determine any association between
2 functional TLR4 mutations (Asp299Gly and
Thr399Ile) with Gram-negative BSI. In our patients
the frequency of minor alleles at both loci were within
the range reported in the literature for Caucasians
(6%-10%) [6]. Because these mutations are in linkage
disequilibrium and are predicted to affect TLR4
signaling, we defined as ‘‘risk genotype,’’ the genotype
heterozygous for the minor allele in both loci.
We did not find any association between risk geno-
type in the donor or recipient and development of BSI
posttransplant. The presence of the risk genpotype in
the donor showed marginal statistical significance in
univariate analysis. Our negative findings may be due
to our limited sample size. To design a larger prospec-
tive study to address the association of TLR4 SNPs
with Gram-negative BSI post-HSCT we used the
power calculation method of Schoenfeld [15] to calcu-
late the sample size required to estimate a desired haz-
ard ratio with 80% power and 5% significance level.
Our observed data shows that 9 (12%) of 77 donor
specimens have a risk genotype. The remaining 68
specimens (88%) have no risk genotype in the donor.
In the absence of any competing cause of infection,
the total number of infections required to detect
a hazard ratio of 3 with 80% power, and 5%
significance level is 62. If 20% of the patients develop
an infection, then the required total sample size is
62/0.25 310 patients. Ideally, the analysis should
take into account the amount of LPS produced by
the pathogens of BSI and host chimerism at the time
of infection.
We report the first prospective study examining
the association of TLR4 polymorphisms with Gram-
negative bloodstream infection after allogenic
HSCT. The ability to predict genetic susceptibility
to a common infection with substantial morbidity is
of direct relevance to the design of strategies to protect
the most vulnerable patients.ACKNOWLEDGMENTS
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